Laura Sepp-Lorenzino

Insider Reports History

Entity
Individual
Location
C/O Intellia Therapeutics, Inc., 40 Erie Street, Suite 130, Cambridge, MA
Signature
/s/ Kamran Alam, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Laura Sepp-Lorenzino:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Intellia Therapeutics, Inc. EVP, Chief Scientific Officer Common Stock 81.9K $2.7M $32.99 Mar 1, 2024 Direct
Intellia Therapeutics, Inc. EVP, Chief Scientific Officer Restricted Stock Unit 3.5K $83.7K $23.90 Jan 1, 2024 Direct
Taysha Gene Therapies, Inc. Director Common Stock 49.2K $74.3K $1.51 May 29, 2024 Direct
Taysha Gene Therapies, Inc. Director Stock Option (right to buy) 98.4K May 29, 2024 Direct
Intellia Therapeutics, Inc. EVP, Chief Scientific Officer Stock Option (right to buy) 54.8K Mar 1, 2024 Direct

Insider Reports Filed by Laura Sepp-Lorenzino

Symbol Company Period Transactions Value $ Form Type Date Filed Role
TSHA Taysha Gene Therapies, Inc. May 29, 2024 2 $0 4 May 31, 2024 Director
NTLA Intellia Therapeutics, Inc. Mar 1, 2024 2 $0 4 Mar 5, 2024 EVP, Chief Scientific Officer
NTLA Intellia Therapeutics, Inc. Jan 8, 2024 2 -$65.7K 4 Jan 10, 2024 EVP, Chief Scientific Officer
NTLA Intellia Therapeutics, Inc. Jan 3, 2024 1 -$163K 4 Jan 5, 2024 EVP, Chief Scientific Officer
NTLA Intellia Therapeutics, Inc. Jan 1, 2024 2 $0 4 Jan 3, 2024 EVP, Chief Scientific Officer
TSHA Taysha Gene Therapies, Inc. Jun 22, 2023 1 $0 4 Jun 26, 2023 Director
NTLA Intellia Therapeutics, Inc. Mar 1, 2023 2 $0 4 Mar 3, 2023 EVP, Chief Scientific Officer
NTLA Intellia Therapeutics, Inc. Jan 4, 2023 3 -$183K 4 Jan 6, 2023 EVP, Chief Scientific Officer
NTLA Intellia Therapeutics, Inc. Jan 1, 2023 2 $0 4 Jan 4, 2023 EVP, Chief Scientific Officer
TSHA Taysha Gene Therapies, Inc. Jun 17, 2022 1 $0 4 Jun 22, 2022 Director
NTLA Intellia Therapeutics, Inc. Mar 1, 2022 1 $0 4/A Mar 4, 2022 EVP, Chief Scientific Officer
NTLA Intellia Therapeutics, Inc. Jan 1, 2022 5 -$129K 4 Mar 3, 2022 EVP, Chief Scientific Officer
NTLA Intellia Therapeutics, Inc. Aug 30, 2021 13 -$13.7M 4 Sep 1, 2021 EVP, Chief Scientific Officer
NTLA Intellia Therapeutics, Inc. Aug 4, 2021 9 -$3.25M 4 Aug 6, 2021 EVP, Chief Scientific Officer
TSHA Taysha Gene Therapies, Inc. Jun 17, 2021 1 $0 4 Jun 21, 2021 Director